(Q36545395)

14 August 2017

1 reference

title

The effects of thiazolidinediones on blood pressure levels - a systematic review (English)

1 reference

14 August 2017

1 reference

Pantelis A Sarafidis

1

1 reference

PubMed ID

16864155

14 August 2017

Peter M Nilsson

series ordinal

2

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

15

1 reference

14 August 2017

3

1 reference

14 August 2017

135-150

1 reference

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

14 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effect of insulin on renal sodium and uric acid handling in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin resistance as cause of increased blood pressure in the elderly: effects on intracellular ion contents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Altered ionic effects of insulin in hypertension: role of basal ion levels in determining cellular responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Type 2 diabetes, cardiovascular risk, and the link to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of ciglitazone on blood pressure and intracellular calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Altered pressure-natriuresis in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Dietary fat-induced increase in blood pressure and insulin resistance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone attenuates diet-induced hypertension in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Antiinflammatory and antiarteriosclerotic effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Risk reduction therapy for syndrome X: comparison of several treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone Lowers Blood Pressure and Increases Arterial Compliance in Postmenopausal Women With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

The effect of rosiglitazone on overweight subjects with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050600853720

10.1080/08037050600853720

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16864155